Sofinnova

EQS-News: Abivax reports 2023 financial results and operational update

Retrieved on: 
Wednesday, April 10, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Abivax reports 2023 financial results and operational update

Retrieved on: 
Tuesday, April 2, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Stifel, EUR, GJB2, Euronext Growth, Patient, Code, Interim, Reserved, Sofinnova, Clinical trial, Commercial code, Person

The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.
  • This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months.
  • The capital increase enables the Company to finance its activities until the end of 2025.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.

Synthace Announces Appointment of Willem Baralt as New Chairman

Retrieved on: 
Wednesday, March 20, 2024
Quanta, Automation, Growth, History, IPO, Doctor of Philosophy, Sofinnova, FDA, Fine chemical

LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.

Key Points: 
  • LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.
  • Mr. Baralt joined the company in February 2024 during a period of accelerating growth, as Synthace expands its offerings.
  • "I am thrilled to welcome Willem aboard," said Guy Levy-Yurista, PhD, CEO of Synthace.
  • "We welcome Willem Baralt's appointment as Chairman of the Board," said Joe Anderson, PhD, Partner at Sofinnova Partners.

Synthace Announces Appointment of Willem Baralt as New Chairman

Retrieved on: 
Wednesday, March 20, 2024
Quanta, Automation, Growth, History, IPO, Doctor of Philosophy, Sofinnova, FDA, Fine chemical

LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.

Key Points: 
  • LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.
  • Mr. Baralt joined the company in February 2024 during a period of accelerating growth, as Synthace expands its offerings.
  • "I am thrilled to welcome Willem aboard," said Guy Levy-Yurista, PhD, CEO of Synthace.
  • "We welcome Willem Baralt's appointment as Chairman of the Board," said Joe Anderson, PhD, Partner at Sofinnova Partners.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
International SOS, Disease, Partnership, International, Patient, Hospitality, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
Disease, Partnership, Patient, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers - those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
International SOS, Disease, Partnership, International, Patient, Hospitality, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
Wednesday, March 20, 2024
Disease, Partnership, Patient, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers - those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Moon Surgical's Maestro System powered by NVIDIA Holoscan paves the way to next-generation laparoscopy, with over 200 patients treated

Retrieved on: 
Tuesday, March 19, 2024
Growth, Surgeon, System, Patient, SAN, Hospital, Health care, Instrument, Moon, Nvidia, Sofinnova, Nursing, Artificial intelligence, Medtech

"Maestro System powered by NVIDIA Holoscan paves the way to next-generation laparoscopy, with over 200 patients treated" - Kimberly Powell, Vice President of Healthcare at NVIDIA

Key Points: 
  • "Maestro System powered by NVIDIA Holoscan paves the way to next-generation laparoscopy, with over 200 patients treated" - Kimberly Powell, Vice President of Healthcare at NVIDIA
    Moon Surgical today announced that over 200 patients have been successfully treated with its Maestro System, powered by NVIDIA Holoscan, which delivers surgeon autonomy in its first commercial use in various surgical interventions.
  • The Maestro System is used in laparoscopy, where surgeons operate through small incisions with an internal camera and instruments.
  • Moon Surgical has now integrated Holoscan into its commercial Maestro System to enable its first computer vision-based capability, the ScoPilot™.
  • "This proof-of-concept showing an AI application running on NVIDIA Holoscan in real-time during Maestro surgery validates the principle behind our platform."